PureTech Founded Entity Akili Announces PLOS ONE Publication of Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx® Activates Systems in Brain Key to Attentional Functioning
Electroencephalography data (EEG) demonstrate enhancement of brain activity specific to attention function in children 8-12 with ADHD following AKL-T01 (EndeavorRx) treatment
Data show correlation between targeted activity in the brain and objective improvements in attention function
Excerpt from the Press Release:
BOSTON–(BUSINESS WIRE)–PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted today that its Founded Entity, Akili Interactive Labs, Inc. (“Akili”), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, announced the publication of full data from a single arm, unblinded study conducted by Dr. Elysa Marco at Cortica Healthcare and Drs. Joaquin Anguera and Courtney Gallen at the University of California, San Francisco. The study measured electroencephalography (EEG) data alongside behavioral and clinical metrics of attention in children with ADHD using AKL-T01 (EndeavorRx). Data from the study show that EndeavorRx treatment resulted in increased brain activity related to attention function, as measured by EEG, which correlated with improvements in objective behavioral measures of attention
In this study, attention in children with ADHD was evaluated using a well-established EEG-based measure of attentional control, midline frontal theta (MFT) activity. Data show that EndeavorRx enhanced MFT activity, suggesting that patients who used EndeavorRx for 4 weeks showed changes in measurable brain function. Study results also demonstrated a correlation between MFT activity and attention functioning, suggesting that children who experienced the largest gains in MFT activity as measured by EEG also showed the greatest improvements in computerized performance tests designed to measure attention. Additionally, parents reported significantly fewer inattention symptoms in children treated with EndeavorRx, as measured by the Vanderbilt ADHD Diagnostic Rating Scale.
The study results were published in the medical journal PLOS ONE.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?